FDA’s Patent And Exclusivity Team Aims To Ensure Timely First Generics
This article was originally published in The Pink Sheet Daily
Executive Summary
Generic drugs office will proactively seek litigation and other information that could affect launch timing.
You may also be interested in...
Generic Exclusivity? Who Cares! Industry Offers Few Opinions On Potential Changes
FDA officials still looking for input after transparency issue not widely addressed during GDUFA policy meeting.
ANDA Expedited Review Criteria MaPPed Out By FDA Generic Drug Office
CDER staff manual outlines seven categories of submissions that can qualify for expedited review, including some ANDAs with patent certifications and supplements that have the potential to create an “extraordinary hardship” for a sponsor if not addressed quickly.
Generics Savings Once Again Could Help A Major US Health Care Reform Bill
A provision in the pending legislation on PBMs that would allow the US FDA to provide qualitative and quantitative information to ANDA sponsors about reference product's inactive ingredients could save hundreds of millions in spending.